MEGAN PICHETTE: Open Payments
NPI 1497491435 · RIVERSIDE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,699 in 99 payments from 39 companies in 2025. Trend: 2023 $3,498 · 2024 $3,538 · 2025 $2,699
Food & beverage: $2,600Long term medical supply or device loan: $100
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 18 | $450 |
| AstraZeneca Pharmaceuticals LP | 7 | $364 |
| Daiichi Sankyo Inc. | 6 | $158 |
| Janssen Biotech, Inc. | 6 | $129 |
| Astellas Pharma US Inc | 1 | $126 |
| Merck Sharp & Dohme LLC | 4 | $110 |
| Regeneron Healthcare Solutions, Inc. | 4 | $108 |
| Eisai Inc. | 3 | $81 |
| Celgene Corporation | 3 | $72 |
| Aveo Pharmaceuticals, Inc. | 2 | $71 |
Products named: KISQALI, CALQUENCE, ENHERTU, IMFINZI, Fabhalta, Vyloy, KEYTRUDA, Lenvima.
Industry payments across CA — which companies pay providers there.
